Literature DB >> 8148477

Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.

G Majumdar1, J K Phillips, H Lavallee, G F Savidge.   

Abstract

A patient with autosomal dominant (Type III) von Willebrand's disease (vWd) developed acquired haemophilia post-operatively, possibly due to exposure to amoxycillin. She refused porcine factor VIII (pFVIII) on religious grounds and was managed successfully with recombinant activated factor VII (rFVIIa) together with highly purified von Willebrand factor concentrate (vWf-VHP). In patients with acquired haemophilia rFVIIa appears to be a suitable agent for symptomatic management.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8148477

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 2.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 3.  Current therapy in children and adolescents with von Willebrand disease.

Authors:  I Buga-Corbu; C Arion
Journal:  J Med Life       Date:  2014-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.